GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Debt-to-Equity

Pharma Equity Group A/S (OCSE:PEG) Debt-to-Equity : 0.78 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Debt-to-Equity?

Pharma Equity Group A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr22.15 Mil. Pharma Equity Group A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr8.07 Mil. Pharma Equity Group A/S's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr38.93 Mil. Pharma Equity Group A/S's debt to equity for the quarter that ended in Dec. 2023 was 0.78.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharma Equity Group A/S's Debt-to-Equity or its related term are showing as below:

OCSE:PEG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.25   Max: 0.78
Current: 0.78

During the past 13 years, the highest Debt-to-Equity Ratio of Pharma Equity Group A/S was 0.78. The lowest was 0.00. And the median was 0.25.

OCSE:PEG's Debt-to-Equity is ranked worse than
82.69% of 1063 companies
in the Biotechnology industry
Industry Median: 0.14 vs OCSE:PEG: 0.78

Pharma Equity Group A/S Debt-to-Equity Historical Data

The historical data trend for Pharma Equity Group A/S's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Debt-to-Equity Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.29 0.45 0.50 0.78

Pharma Equity Group A/S Quarterly Data
Mar16 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.35 0.39 0.44 0.78

Competitive Comparison of Pharma Equity Group A/S's Debt-to-Equity

For the Biotechnology subindustry, Pharma Equity Group A/S's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Debt-to-Equity falls into.



Pharma Equity Group A/S Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharma Equity Group A/S's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Pharma Equity Group A/S's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Equity Group A/S  (OCSE:PEG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Pharma Equity Group A/S Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.